0000000000306381

AUTHOR

C Germinario

showing 2 related works from this author

Molecular characterization of rotavirus strains from children with diarrhea in Italy, 2007-2009.

2011

The surveillance network RotaNet-Italia was established in 2007 in order to investigate the diversity of co-circulating rotavirus strains in Italy, and to provide a baseline for future assessment of possible effects of vaccine implementation in selecting novel versus common rotavirus strains. A total of 2,645 rotavirus strains from pediatric patients with acute diarrhea were collected over three consecutive seasons from September 2006 through August 2009, and partially characterized by standardized multiplex RT-PCR. Most of strains (89.1%) belonged to genotypes G1–G4, and G9, associated with either P[8] or P[4], commonly found in humans worldwide. However, in at least 2.0% of cases, viruses…

DiarrheaRotavirusGenotypingSettore MED/07 - Microbiologia E Microbiologia ClinicavirusesgenotypeReassortmentBiologymedicine.disease_causePolymerase Chain ReactionRotavirus Infectionslaw.inventionstrainlawVirologyRotavirusGenotypeGenetic variationmedicineHumansGenotypingPolymerase chain reactionBase SequenceMolecular epidemiologyInfant NewbornRotavirus VaccinesGenetic VariationInfantSequence Analysis DNARotaviruVirologyRotavirus.DiarrheaInfectious DiseasesItalyChild PreschoolMolecular epidemiologysurveillanceRNA Viralmedicine.symptomRotavirus; strain; genotype.Reassortant Viruses
researchProduct

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in…

0301 basic medicineMalePediatricsEpidemiologyvirusesInfluenza B viruinfluenza ; influenza vaccine effectiveness ; influenza vaccination ; case control study ; multicentre study ; EuropeEurope case control study influenza influenza vaccination influenza vaccine effectiveness multicentre study0302 clinical medicineInfluenza A Virus H1N1 Subtype[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInteriminfluenza vaccine effectivenessEpidemiologyPandemicInfluenza A Virus030212 general & internal medicineQAInfluenza vaccine effectivenessChildmedia_commonVaccine EffectivenessVaccinationvirus diseasesMiddle Agedinfluenza vaccinationmulticentre study3. Good healthVaccinationEuropeTreatment OutcomeInfluenza VaccinesChild PreschoolH3N2 SubtypeFemaleSeasonsInfluenza VaccineinfluenzaRapid CommunicationHumanAdultRMmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyCase control studyMulticentre studyEuropean studiesSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesVirologyInfluenza Humanmedicinemedia_common.cataloged_instanceHumansH1N1 SubtypeVacina AntigripalEuropean UnionEuropean unionPreschoolPandemicsAgedPandemicInfluenza A Virus H3N2 SubtypeCuidados de SaúdePublic Health Environmental and Occupational HealthInfant NewbornInfantInfluenza ainfluenza vaccine effectivenecase control studyNewbornEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre studyInfluenzarespiratory tract diseasesInfluenza vaccinationInfluenza B virusEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; Adolescent; Adult; Aged; Child; Child Preschool; Europe; European Union; Female; Humans; Infant; Infant Newborn; Influenza A Virus H1N1 Subtype; Influenza A Virus H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza Human; Male; Middle Aged; Pandemics; Treatment Outcome; Vaccination; Seasons[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDeterminantes da Saúde e da Doença[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
researchProduct